217 related articles for article (PubMed ID: 25344116)
1. OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.
Madden SF; Clarke C; Stordal B; Carey MS; Broaddus R; Gallagher WM; Crown J; Mills GB; Hennessy BT
Mol Cancer; 2014 Oct; 13():241. PubMed ID: 25344116
[TBL] [Abstract][Full Text] [Related]
2. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome.
Madden SF; Clarke C; Gaule P; Aherne ST; O'Donovan N; Clynes M; Crown J; Gallagher WM
Breast Cancer Res; 2013; 15(4):R52. PubMed ID: 23820017
[TBL] [Abstract][Full Text] [Related]
3. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
Tuncer SB; Erdogan OS; Erciyas SK; Saral MA; Celik B; Odemis DA; Turkcan GK; Yazici H
J Ovarian Res; 2020 Aug; 13(1):99. PubMed ID: 32854743
[TBL] [Abstract][Full Text] [Related]
4. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.
Lánczky A; Nagy Á; Bottai G; Munkácsy G; Szabó A; Santarpia L; Győrffy B
Breast Cancer Res Treat; 2016 Dec; 160(3):439-446. PubMed ID: 27744485
[TBL] [Abstract][Full Text] [Related]
5. The modularity and dynamicity of miRNA-mRNA interactions in high-grade serous ovarian carcinomas and the prognostic implication.
Zhang W; Edwards A; Fan W; Flemington EK; Zhang K
Comput Biol Chem; 2016 Aug; 63():3-14. PubMed ID: 26949157
[TBL] [Abstract][Full Text] [Related]
6. Pathway-based classification of cancer subtypes.
Kim S; Kon M; DeLisi C
Biol Direct; 2012 Jul; 7():21. PubMed ID: 22759382
[TBL] [Abstract][Full Text] [Related]
7. A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.
Calura E; Paracchini L; Fruscio R; DiFeo A; Ravaggi A; Peronne J; Martini P; Sales G; Beltrame L; Bignotti E; Tognon G; Milani R; Clivio L; Dell'Anna T; Cattoretti G; Katsaros D; Sartori E; Mangioni C; Ardighieri L; D'Incalci M; Marchini S; Romualdi C
Ann Oncol; 2016 Aug; 27(8):1511-9. PubMed ID: 27194815
[TBL] [Abstract][Full Text] [Related]
8. Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence.
Delfino KR; Rodriguez-Zas SL
PLoS One; 2013; 8(3):e58608. PubMed ID: 23554906
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
10. Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Laios A; O'Toole S; Flavin R; Martin C; Kelly L; Ring M; Finn SP; Barrett C; Loda M; Gleeson N; D'Arcy T; McGuinness E; Sheils O; Sheppard B; O' Leary J
Mol Cancer; 2008 Apr; 7():35. PubMed ID: 18442408
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
Li Y; Li L
J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
[TBL] [Abstract][Full Text] [Related]
13. Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer.
Zhang W; Zang J; Jing X; Sun Z; Yan W; Yang D; Shen B; Guo F
J Transl Med; 2014 Mar; 12():66. PubMed ID: 24618011
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
15. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
[TBL] [Abstract][Full Text] [Related]
16. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
17. Identification of the miRNA signature associated with survival in patients with ovarian cancer.
Sathipati SY; Ho SY
Aging (Albany NY); 2021 Apr; 13(9):12660-12690. PubMed ID: 33910165
[TBL] [Abstract][Full Text] [Related]
18. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.
Yin F; Yi S; Wei L; Zhao B; Li J; Cai X; Dong C; Liu X
J Cell Biochem; 2019 Apr; 120(4):6057-6070. PubMed ID: 30335894
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.
Liu N; Chen NY; Cui RX; Li WF; Li Y; Wei RR; Zhang MY; Sun Y; Huang BJ; Chen M; He QM; Jiang N; Chen L; Cho WC; Yun JP; Zeng J; Liu LZ; Li L; Guo Y; Wang HY; Ma J
Lancet Oncol; 2012 Jun; 13(6):633-41. PubMed ID: 22560814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]